A hormone the body makes to switch on puberty also slowed a hard-to-treat cancer in the lab, and it did it without touching the mutated gene that was driving the tumor.
The hormone is kisspeptin, a 54-amino-acid peptide the brain releases to start puberty and keep the reproductive cycle running. It has a second, older reputation. Before it was known as the puberty signal, the gene that makes it (KISS1) was flagged as a metastasis suppressor, a natural brake on the spread of cancer, and its peptide product even carried the name metastin. A study published in the August issue of Anticancer Research ↗ tried to pin down how that brake works against one of the most stubborn drivers in cancer biology.
That driver is RAS. A mutated, always-on version of RAS is one of the most common engines of human tumors, and it has resisted drugs for forty years. The paper used a specific mutant, HRAS-G12V, engineered into mouse cells to make them cancerous.
Cutting a link the drug hunters skip
The interesting move here is where kisspeptin acts. It does not bind RAS. It does not try to switch the mutated gene off. Instead it works on kisspeptin's own receptor, KISS1R, a cell-surface protein, and sends a signal down a chain (through the small proteins Gaq/11 and RhoA) that ends at a switch called SP1. SP1 is a transcription factor, a protein that turns other genes on by docking onto their control regions. In these cancer cells, RAS was using SP1 to crank up a gene called N-cadherin, a molecule that helps tumor cells loosen from each other and travel. That is the machinery of metastasis.
Kisspeptin signaling, the authors report, kept SP1 from docking on the N-cadherin control region. With that one link cut, the cells made less N-cadherin, and they proliferated, migrated, and invaded less. In mice, cells carrying the RAS mutation grew smaller tumors and seeded fewer lung metastases when kisspeptin signaling was switched on. When the researchers forced N-cadherin back up, the protection went away. That last step is the tell: it points to N-cadherin as the actual thing the peptide was working through, not a bystander.
The strategy is worth naming. Most of the effort against RAS goes at RAS itself, or at the mutation. Yesterday this section covered an oral cyclic peptide that binds RAS directly ↗ across many mutant forms. This is the opposite bet. Leave the undruggable oncogene alone and shut one of the downstream switches it depends on to spread.
What this is, and what it is not
This is a laboratory mechanism paper, and the honest frame matters. The work was done in NIH3T3 cells, an immortalized mouse fibroblast line that has been the standard bench tool for studying RAS transformation for decades. The cancer was engineered in, and kisspeptin was not given as a drug. The researchers, Hyun-Ha Hwang of Kyung Hee University in Seoul and Sung-Gook Cho of Korea National University of Transportation, raised kisspeptin signaling genetically inside the cells rather than injecting the peptide. So this shows a route, not a treatment. HRAS-G12V also is not the most common RAS mutation in patients (KRAS is), which narrows how far the specific finding travels.
What it adds is a concrete, testable chain: KISS1R to SP1 to N-cadherin. Kisspeptin is not a stranger to the clinic. Synthetic kisspeptin-54 has been tested in fertility medicine as a gentler trigger for egg maturation, so the safety profile of the peptide in people is not a blank slate. That does not make it a cancer drug. It does mean the receptor at the top of this chain, KISS1R ↗, is a real, drug-reachable target rather than a theoretical one, and the peptide that hits it, kisspeptin-54 ↗, is a known quantity.
The catch with any single mechanism paper is that a clean pathway on the bench often frays in a living tumor, where SP1 and N-cadherin answer to more than one boss. The value of this one is that it hands the next lab a specific arrow to test and a way to check it: block the SP1 to N-cadherin step, watch metastasis, and see whether the brake holds outside a dish.